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WHILE there is a vast literature on the effects of oestrogens and androgens on
tumours, only a few reports have appeared in the last two or three years on
clinical experience with progestins in human cancer. Kelley and Baker (1961).
have treated 21 cases ofuterine cancer using variouspreparations ofprogestational
agents. Stoll (1961) treated 2 patients with oral progestational steroid (Enavid)
and noted a regression of their recurrent endometrial carcinomata. No reports
on cases of malignant ovarian tumours andveryfew on breast cancertreated with
progesterone were found in the literature. Twelve cases of advanced mammary
carcinoma were treated by Douglas, Loraine and Strong (1960) who studied the
effects of 19-norethistosterone oenanthate, an early non-marketed German
product. Only one patient in their series showed a favourable response. The
indications for the use of a hormone which appears to exert its biological activity
through an influence on connective tissue structures need hardly be stressed.
The availability ofa long acting progesterone preparation in the form ofPrimolut
Depot (Delalutin in U.S.A.) prompted, in 1957, the start of a study ofits growth-
restraining effects in a small series of cases of advanced malignant tumours of
breast, ovary and uterus. The findings and the discussion of the rationale of
treatment are the subject of this preliminary note.
THE HORMONE AND CLINICAL MATERIAL
It is generally accepted that the pharmacological properties of synthetic
progesterone are comparable to natural corpus luteum hormone. The disadvant-
age of its low solubility, hence underdosage in clinical use, has been overcome by
the development of hydroxyprogesterone capronate by hydrolysis from proges-
terone. Concentrated in Primolut Depot-up to 250 mg. in 1 ml. of oily solution
it has an activity lasting over one week. Other derivatives such as 17a-alkyl-
19-nor-testosterone (Junkmann, 1954) with the trade name of Primolut N and
17ac-ethinyl-17-hydroxy-5(10)-oestren-3-one, enhanced by etbinyloestradiol 3-
methyl ether, marketed as Enavid, have the advantage of a marked oral activity.
The capronate form has a progestational action, prompt and twice as marked
and 2 to 4 times more prolonged than free progesterone. Kistner (1958) claims
that Primolut Depot in comparison with free 17a-hydroxyprogesterone is 30
times more effective and 5 times more prolonged in its action. It is claimed to
have a weak anti-gonadotrophic action and, similar to progesterone, little
effect on the menstrual cycle. It has shown no androgenic effects in animal
experiments (Suchowsky and Junkmann, 1961).
* Based on a paper read at the 2nd Annual Conference of the British Association of Cancer
Research held at the Middlesex Hospital Medical School, London, on September 16, 1961.4 0
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215B. JOLLES
Twenty-seven patients with tumours of the breast, ovary and uterus, in
very advanced stages, in which other methods of treatment-surgery, radio-
therapy, oestrogens or androgens or chemotherapy have failed or have lost
their effectiveness have been treated.
Of the 27 cases here reviewed there were 9 cases of carcinoma of breast, 10
cases of carcinoma of the ovary and 8 cases of malignant tumours of the uterus
(2 cervical cases). The dosage was 250 mg. once a week; in 2 cases the com-
pound was given in tablet form-Norethisterone-30 mg. daily.
The Primolut Depot, 17x-hydroxyprogesterone capronate, has not in this
series caused any untoward side effects. There were no reactions at the site of
the injections.
Fifteen patients have shown subjective improvement, with increased appetite
and a sense of well being. In some, objective signs of improvement were noted.
Table I shows the response to progesterone treatment assessed on the basis of
clinical and radiological findings, and the statements of the patients' own general
practitioners, and patients themselves concerning their objective and subjective
improvement.
TABLE I.-Ca8es Reviewed 27
Atalignant Number Clinical response
tumours of ,
of: patients Good Fair None
Breast . . 9 . 3 2 4
Ovary . 10 4 1 5
Uterus 8 3 2 3
Details of age, histology, previous surgery, radiotherapy, hormonetherapy
or chemotherapy, the dosage of progesterone administered and response are
set out in Tables II, III and IV.
In the series of 9 cases ofadvanced carcinoma ofbreast, the outstanding success
of treatment with progesterone was that of Case 2 with skin recurrences in the
pectoral region and abdominal metastases, and subsequently a tumour mass in
the opposite breast which remains quiescent. This patient is doing well and has
been on progesterone for over 31 years, with a total dose of nearly 60,000 mg.
Not only were there no untoward side effects but the patient's well-being has
been maintained throughout. The suggestion made to the patient to discontinue
progesterone for a while in order to enable an assessment of its real subjective
value met with a flat refusal because of the experience gained from the occasional
omission or delay of the weekly dose which had brought a deterioration in the
patient's general condition, unduly easy fatigue and a sensation which can only
be described as that of deprivation.
Similar statements were volunteered by 2 other patients. One with leiomyo-
sarcoma of the uterus (Case 20) who has benefited both subjectively and objec-
tively (reduction in size of palpable mass in pelvis, abolition of pain and improve-
ment of general condition), and a patient with an ovarian tumour (Case 13) with
ascites and bilateral pleural effusions, in whom progesterone was thought to be
responsible for the drying up of the pleural effusion altogether until the time of
death, and had at first also prolonged considerably the period between paracen-
teses. The latter, however, had to be subsequently resumed. In this patient
clinically the undoubted effect was short lived (3 months), but it must be added
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that this particular patient had received also, at the beginning of the series of
progesterone injections, nitrogen mustard (Thiotepa, 5 x 15 mg.).
In the other cases in whom the results were noted as " fair improvement"
there was no doubt of the slight amelioration ofthe patients' condition. It must
be stressed, however, that the dosage has been on the low side, and it seems that
at least initially a dose of 500 mg. weekly is indicated.
The drying up ofthe ascites and pleural effusions after progesterone treatment
was the outstanding feature in Case 13, and of ascites in Cases 10 and 17.
Similar results were observed by Kelley and Baker (1961) who used various
preparations ofprogestational agents including aqueous suspension ofprogesterone
in oil and 17 ac-hydroxyprogesterone capronate in weekly doses ranging from 150
to 1000 mg. Six out of 21 patients with endometrial carcinoma benefited
(5 showed regression of pulmonary metastases), the remissions lasting from 9
months to 4- years. Three of these died; in one the disease progressed and two
enjoyed a remission on continual progesterone therapy.
Of the few results of treatment with free progesterone used, before synthetic
preparations allowing the administration of high dosages were available, the
following are worth recording. While Hertz, Cromer, Young and Westfall (1951)
noticed visible and palpable regression of carcinoma of cervix uteri in 11 out of
17 patients treated with free progesterone, Gordon, Horwitt Segaloff, Murisonand
Schlosser (1952) noted improvement only in 2 out of 20 patients with breast
cancertreatedwithfreeprogesterone, and Volk, Escher, Huseby, Tylerand Cheda
(1960) had no success with oral progesterone (2000 mg. daily) in 29 post meno-
pausal women with advanced breast carcinoma. The only case of carcinoma of
breast (Geller, Volk and Lewin, 1961) treated with synthetic progesterone was
that of a male patient whose secondary bone deposits showed recalcification after
treatment with 17 a-hydroxyprogesterone--250 mg. daily.
DISCUSSION
No impressive results could be expected in the group ofpatients here described,
and the response noted as fair was that which is encountered in a proportion of
cases treated with oestrogens or androgens. When, however, allowance is made
for the inadequate amounts ofprogesterone actually taken because ofthe terminal
stage at which the treatment was instituted and the interesting observations of
reduction in size of tumour, drying up of effusions and subjective improvements
produced, the value ofprogestins in treatment ofsome tumours appears to warrant
a further study of their effects in malignant disease. As a sound approach to
hormone therapy must be based not only on research in the endocrinological and
clinical fields, but have a background ofideas concerning the mechanism of action
of a new compound, i.e. a rationale for its application, a discussion of the latter
seems desirable. For this reason the effects of progestins on the humoral and
tissue levels will be briefly discussed.
The mechanism of action of progestins is not clear. It is worth mentioning
that Jenkins (1961), who has described the effects of progesterone in cyclical
ascites, is of the opinion that the electrolyte excretion plays an important role
in this respect, progesterone acting as an aldosterone antagonist. This is probably
borne out by the effects on ascites and pleural effusion in the cases of ovarian
tumour.
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is not certain whether all progestins have an inhibitory effect on gonadotrophin
secretion. It is assumed that Primolut Depot has very little direct effect on the
pituitary. Other progesterones may have different mechanisms of action. The
group of Edinburgh workers (Douglas, Loraine and Strong, 1960) found that
19-norethistosterone oenanthate in 12 cases of mammary carcinoma had little
effect, only one case showing improvement. However, there are differences
in the metabolism and physiological effects of the two progesterones, and this
aspect awaits further investigation. In Table V are set out data concerning the
metabolism of a few progestins and their side effects.
TABLE V.-Effects of some Progestins
Free
progesterone
Pituitary gonado- Inhibition
trophins
Oestrogen excrb- Increased
tion
Androgenic ? or ?
anabolic effects
Total 17-oxo- Increase in
steroid and hy- pregnanendiol
droxycortico-
steroid excretion
Electrolytes Ca, K, Aldosterone
Na, N, Cl. antagonist
17 a-hydroxy-
progesterone
19-Norethi- capronate
sterone (Primolut Depot)
Reduced, but not . Weak antigonado-
abolished trophin
. Increased, variable
oestrinisation or
little change
. Not reduced. Not
depressed. ACTH
increased
. No change (Lor-
aine).
Slight retention of
Na (Jenkins)
Norethynodrel
(Enavid)
. Reduced but
not sup-
pressed.
Not affected, no ef- . Increased.
fect on menstrual
cycle
-No virilising effects
in animals. Possible
anabolic effect
Not converted into . Decreased.
progesterone, an-
drogens or cortico-
steroids.
Decrease in urinary . Reduced pi
pregnanendiol. nanendiol.
ACTHnot increased
Increased excretion .
of Na.
Aldosterone anta-
gonist
Treg-
Titres of follicle-stimulating hormone in one patient measured by Kelley and
Baker (1961) showed no suppression ofthe pituitary during treatment. Sherman
and Woolf (1959) noted a drop in elevated levels of luteinizing hormone in 4
patients with carcinoma ofthe endometrium who received 17-hydroxyprogesterone
capronate for six weeks. As these authors do not state whether there has been
tumour regression in their cases the question of an effect via the pituitary gland
remains an open one.
Sherman and Woolf (1959) suggest that in cases of endometrial carcinoma an
increased LH production exercises an influence on an abnormally high comple-
ment of hilar (Leydig or theca) cells which are kept in check during reproductive
years by progesterone derived from successive corpora lutea. After menopause
this restraint is no longer available and the ensuing excessive oestrogen pro-
duction is followed by an endocrinal pattern leading through a phase of cystic
adenomatous hyperplasia and anaplasia to carcinoma. By introducing into the
body of a hormone which may act by the proper feed-back action on the pituitary
the endocrine pattern, as suggested by these authors, might be interfered with
either prophylactically or as a curative measure in established neoplasia.
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Kistner (1958) who studied the effect of 17ax-hydroxyprogesterone in endo-
metriosis suggests that the esterified steroid is transported intact to the tissues
where it exerts its biologic activity, and there is slowly metabolized as it induces
its action. Brown, Fotherby and Loraine (1960) in their study of the effects of 17x-ethinyl-19-norethisterone on the urinary excretion of oestrogens, pregnanen-
diol and gonadotrophins during the menstrual cycle postulate that norethisterone
exerts its effect by a direct action on the ovary rather than through the pituitary.
It is generally assumed that oestrogens exert their influence on malignant cells
directly, and little attention has been paid to histological changes produced in
intercellular structures deeply affected both structurally and functionally by
steroids. The importance of these changes cannot be over-rated.
Facts regarding histological changes by endocrine glands on connective tissue
are very fragmentary. Important clues concerning the anatomical and functional
state of tissues in hormone dependent organs (uterus, breast) come from observa-
tions of the physiological changes which these organs undergo during lactation,
the menstrual cycle and in the menopause. The oedema of the stroma in the
proliferative and secretory phases of the menstrual cycle, followed by the des-
truction and shedding of this structure with the menstruating endometrium
(Zuckerman, 1949) is most interesting in this context.
Muller (1951) found that the effects of subcutaneously injected oestrogen on
loose connective tissue in rats were different from those on the dense connective
tissue. In the former oestrogen induced a rejuvenation process, as shown by the
development of a fine reticular network and an increase of ground substance,
while in the dense connective tissue it induced a maturation process with an in-
crease in the denseness and number of collagen bundles.
Pliske (1953) found in guinea-pigs marked hypertrophy of epidermal cells
and swelling of the collagen fibre bundles producing a nearly homogeneous con-
dition in the tissue with interfibrous vacuoles containing degenerating fibroblast
nuclei appearing regularly between the fibre bundles.
Jolles, Greening, Dun and Timms (1956) found in a series of rabbits' ears
treated with local estrogen applications that the most marked changes were in
the epidermis and the collagen of the dermis.
In the epidermis, contrary to the findings of Pliske (1953), no decrease in
the number of layers of epidermal cells was noted; an increase in these was found
constantly in the experimental and control ears in the latter due probably to
oestrogen released into the circulation. In the dermis, swelling of the collagen
fibres and an appearance of
"homogeneity " of the dermis appeared to be char-
acteristic. Examination of fibres by means of electron microscopy did not reveal
changes in the amount of coating material noted in experiments in which a rever-
sible
"maturation " of collagen (characterized by a decrease due to dispersal or
clearing of coating material of collagen fibrils) was induced by mechanical means
such as stretching.
The
"antifibromatogenic " (Lipschuitz, 1950) effect of progesterone has been
known for a long time, but the main indications for its use in the gynaecological
field have been endometriosis, dysmenorrhoea and threatened habitual abortion.
The effects of progesterone on experimental tumour growth is that of accelera-
tion on the one hand (Ehrlich tumours in rats)- latency period halved, followed
by rapid growth, while on the other hand if the rats were pretreated with pro-
gesterone their survival was prolonged (Rio, 1957).
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A compound such as synthetic progesterone which has the effect ofa " decidual
transformation" of the endometrial stroma may play an important role in the
management of tumours in hormone-dependent organs. Changes in tumour
stroma and mesenchymal tissues in general may affect not only the rate of spread
but induce a regression of tumour when the prevailing conditions are rendered
unfavourable. The physio-chemical state of intercellular tissue components,
the degree of their imbibition, the state of the connective tissue ground substance
in tumour and tumour bed have to be considered. It is relevant to recall the
fact that oedema unfavourably influences tumour response in radiotherapy.
Changes in tumour stroma and tumour bed brought about by ionizing radiation
represent a relevant part of the beneficial reaction leading to the destruction of
tumour and repair (Jolles and Koller, 1950; Jolles, 1953). Untimely and
excessive fibrosis in irradiated tumours may on occasion jeopardize the outcome
of treatment. Thus, a hormone which causes the disappearance of fibrosis in
endometriosis could be used with advantage as a coadjuvant of other forms of
therapy.
The key position of progestins in steroid metabolism renders this hormone
interesting when one considers the advisability of an attack on many fronts
at an early stage of malignant disease. The clinical observations made in the
series of cases described are encouraging enough and it is hoped that further
experience in less advanced stages of malignant disease will throw more light on
this and related problems.
SUMMARY
Twenty-seven patients with advanced malignant tumours of the breast (9),
ovary (10) and uterus (8) were treated with a progesterone steroid 17a-hydroxy-
progesterone capronate. A good response was noted in 10 cases. A rationale
oftreatment and the possible mechanisms ofaction ofthis hormone are discussed.
I wish to thank my surgical andgynaecological colleagues fortheir co-operation
andMr. G. Raivid, M.P.S., ofPharmethicals (London) Ltd. for the supply of Prim-
olut in the early stages of the investigation.
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